BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11315565)

  • 1. Hydrolysis of the tumor-inhibiting ruthenium(III) complexes HIm trans-[RuCl4(im)2] and HInd trans-[RuCl4(ind)2] investigated by means of HPCE and HPLC-MS.
    Küng A; Pieper T; Wissiack R; Rosenberg E; Keppler BK
    J Biol Inorg Chem; 2001 Mar; 6(3):292-9. PubMed ID: 11315565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigations into the interaction between tumor-inhibiting ruthenium(III) complexes and nucleotides by capillary electrophoresis.
    Küng A; Pieper T; Keppler BK
    J Chromatogr B Biomed Sci Appl; 2001 Aug; 759(1):81-9. PubMed ID: 11499632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties.
    Battistin F; Scaletti F; Balducci G; Pillozzi S; Arcangeli A; Messori L; Alessio E
    J Inorg Biochem; 2016 Jul; 160():180-8. PubMed ID: 26920229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.
    Reisner E; Arion VB; Guedes da Silva MF; Lichtenecker R; Eichinger A; Keppler BK; Kukushkin VY; Pombeiro AJ
    Inorg Chem; 2004 Nov; 43(22):7083-93. PubMed ID: 15500346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
    Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
    J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-selective inhibition of angiogenesis development by NAMI-A analogues.
    Oszajca M; Collet G; Stochel G; Kieda C; Brindell M
    Biometals; 2016 Dec; 29(6):1035-1046. PubMed ID: 27812766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP.
    Schluga P; Hartinger CG; Egger A; Reisner E; Galanski MS; Jakupec MA; Keppler BK
    Dalton Trans; 2006 Apr; (14):1796-802. PubMed ID: 16568190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles.
    Büchel GE; Gavriluta A; Novak M; Meier SM; Jakupec MA; Cuzan O; Turta C; Tommasino JB; Jeanneau E; Novitchi G; Luneau D; Arion VB
    Inorg Chem; 2013 Jun; 52(11):6273-85. PubMed ID: 23659478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and reactivity of the aquation product of the antitumor complex trans-[Ru(III)Cl4(indazole)2]-.
    Cebrián-Losantos B; Reisner E; Kowol CR; Roller A; Shova S; Arion VB; Keppler BK
    Inorg Chem; 2008 Jul; 47(14):6513-23. PubMed ID: 18553904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isomeric [RuCl2(dmso)2(indazole)2] complexes: ruthenium(II)-mediated coupling reaction of acetonitrile with 1H-indazole.
    Reisner E; Arion VB; Rufińska A; Chiorescu I; Schmid WF; Keppler BK
    Dalton Trans; 2005 Jul; (14):2355-64. PubMed ID: 15995743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
    Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
    J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339.
    Büchel GE; Kossatz S; Sadique A; Rapta P; Zalibera M; Bucinsky L; Komorovsky S; Telser J; Eppinger J; Reiner T; Arion VB
    Dalton Trans; 2017 Sep; 46(35):11925-11941. PubMed ID: 28850133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.
    Bacac M; Hotze AC; van der Schilden K; Haasnoot JG; Pacor S; Alessio E; Sava G; Reedijk J
    J Inorg Biochem; 2004 Feb; 98(2):402-12. PubMed ID: 14729322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics and mechanism of the reduction of (ImH)[trans-RuCl4(dmso)(Im)] by ascorbic acid in acidic aqueous solution.
    Brindell M; Piotrowska D; Shoukry AA; Stochel G; van Eldik R
    J Biol Inorg Chem; 2007 Aug; 12(6):809-18. PubMed ID: 17503095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential.
    Jakupec MA; Reisner E; Eichinger A; Pongratz M; Arion VB; Galanski MS; Hartinger CG; Keppler BK
    J Med Chem; 2005 Apr; 48(8):2831-7. PubMed ID: 15828821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NO Releasing and Anticancer Properties of Octahedral Ruthenium-Nitrosyl Complexes with Equatorial 1 H-Indazole Ligands.
    Orlowska E; Babak MV; Dömötör O; Enyedy EA; Rapta P; Zalibera M; Bučinský L; Malček M; Govind C; Karunakaran V; Farid YCS; McDonnell TE; Luneau D; Schaniel D; Ang WH; Arion VB
    Inorg Chem; 2018 Sep; 57(17):10702-10717. PubMed ID: 30106571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactions of potent antitumor complex trans-[Ru(III)Cl4(indazole)2]- with a DNA-relevant nucleobase and thioethers: insight into biological action.
    Egger A; Arion VB; Reisner E; Cebrián-Losantos B; Shova S; Trettenhahn G; Keppler BK
    Inorg Chem; 2005 Jan; 44(1):122-32. PubMed ID: 15627368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, Characterization and Solution Chemistry of trans-Indazoliumtetrachlorobis(Indazole)Ruthenate(III), a New Anticancer Ruthenium Complex. IR, UV, NMR, HPLC Investigations and Antitumor Activity. Crystal Structures of trans-1-Methyl-Indazoliumtetrachlorobis-(1-Methylindazole)Ruthenate(III) and its Hydrolysis Product trans-Monoaquatrichlorobis-(1-Methylindazole)-Ruthenate(III).
    Lipponer KG; Vogel E; Keppler BK
    Met Based Drugs; 1996; 3(5):243-60. PubMed ID: 18472901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The binding properties of two antitumor ruthenium(III) complexes to apotransferrin.
    Kratz F; Hartmann M; Keppler B; Messori L
    J Biol Chem; 1994 Jan; 269(4):2581-8. PubMed ID: 8300587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational Electrochemistry of Ruthenium Anticancer Agents. Unprecedented Benchmarking of Implicit Solvation Methods.
    Chiorescu I; Deubel DV; Arion VB; Keppler BK
    J Chem Theory Comput; 2008 Mar; 4(3):499-506. PubMed ID: 26620790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.